p53 is the tumor suppressor
transcription factor that activates to various stimulus, including uncontrolled
cell proliferation, oncogene over-expression, and DNA damage. p53 antigen
modulators helps in preventing cancer development through regulation of cell
cycle and apoptosis. Thus, new opportunities in cancer immunotherapy are
expected to develop better drug candidates targeting p53, with complete understanding
of interactions between p53 and the immune system, to avoid various adverse
events. The major challenge is prevention of tissue damage by selectively
modulating p53 activity, under pathophysiological conditions that generate
redox stress.
p53 antigen
modulator therapies are being widely studied for the development of various
target specific cancer therapies. Dendritic cell-derived vaccines, adenoviral
p53 vectors, MDM2 inhibitors and small-molecules to reinstate the DNA binding
activity of p53 are some commercial approaches as p53 antigen modulator
therapies, for the treatment of various indications. Also, research studies
have demonstrated that novel therapeutic strategies are being developed to
overcome the challenges related to in-depth knowledge of p53 and associated
pathways.
Request
to Get the Sample Pages at:
Quark
Pharmaceuticals Inc. is developing QPI-1002 as a nuclease-resistant, synthetic
double-stranded RNA oligonucleotide designed to temporarily inhibit the
expression of the pro-apoptotic gene p53, for the treatment of delayed graft
function and acute kidney injury. Some of the companies having a therapeutic
pipeline of p53 antigen modulators include Innovation Pharmaceuticals Inc.,
Aprea Therapeutics, and Actavalon Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with detailed analysis of
pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licencing, grants, technology
and others.
No comments:
Post a Comment